必贝特 ：科创板IPO今起申购 首创抗癌药填补临床治疗空白

Core Insights - Guangzhou Bibet Pharmaceutical Co., Ltd. has initiated its application for the Sci-Tech Innovation Board, moving closer to entering the capital market [1] - The approval of BEBT-908, a first-in-class dual-target inhibitor, marks a significant milestone for the company and the broader biopharmaceutical industry in China [2][4] Company Developments - BEBT-908 has been approved for treating relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL), demonstrating a median overall survival (OS) increase from 4.0-4.7 months to 8.8 months in clinical trials [2] - The company aims to raise approximately 160 million yuan through its IPO, which will be allocated to new drug development, production facility construction, and working capital [3] - Bibet has established a diverse R&D pipeline covering oncology, autoimmune diseases, and metabolic diseases, with one innovative drug already approved and several others in various clinical trial phases [3] Industry Context - The approval of BEBT-908 and the company's successful listing on the Sci-Tech Innovation Board reflect advancements in China's biopharmaceutical sector and the capital market's support for innovative drug companies [4] - The recent policy changes by the China Securities Regulatory Commission (CSRC) facilitate the listing of unprofitable hard-tech companies with core technologies, providing a pathway for companies like Bibet to connect R&D with capital [1][4]